Related Experiment Video

Updated: Oct 6, 2025

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Empagliflozin-A New Chance for Patients with Chronic Heart Failure

Klaudia Kowalska1, Justyna Walczak1, Joanna Femlak1

  • 1Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland.

Pharmaceuticals (Basel, Switzerland)
|January 21, 2022
PubMed

Insights

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, like empagliflozin, offer new hope for heart failure (HF) patients. These drugs provide cardioprotective benefits beyond blood sugar control, improving patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Endocrinology

Background:

  • Heart failure (HF) presents a growing global healthcare challenge, exacerbated by an aging population and lifestyle factors.
  • New therapeutic strategies are crucial for improving HF patient prognosis and quality of life.
  • Sodium-glucose co-transporter 2 (SGLT-2) inhibitors represent a significant advancement in HF treatment, as recognized by the European Society of Cardiology in 2021.

Purpose of the Study:

  • To review the cardioprotective mechanisms of empagliflozin in patients with chronic heart failure.
  • To evaluate the benefits and effectiveness of empagliflozin for heart failure treatment.

Main Methods:

  • Review of existing scientific literature on empagliflozin and its effects in heart failure.
  • Analysis of the pleiotropic effects of empagliflozin, including nephroprotection, improved endothelial function, blood pressure reduction, and weight management.

Main Results:

  • Empagliflozin, initially developed for diabetes, demonstrates beneficial effects beyond glycemic control.
  • The drug exhibits pleiotropic actions, contributing to cardiovascular protection.
  • Findings suggest empagliflozin is advantageous and effective in heart failure treatment, despite potential limitations.

Conclusions:

  • Empagliflozin offers significant benefits for patients with chronic heart failure.
  • Its pleiotropic effects contribute to its cardioprotective role.
  • Empagliflozin represents a valuable therapeutic option for managing heart failure.

Keywords:
SGLT2 inhibitorscardioprotectioncardiovascular diseasescardiovascular pharmacotherapydiabetesempagliflozinheart failure

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease08:15

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

689

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
40
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
551
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
48
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
519
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
462
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
782